NDC product
Arepanrix
NDC 58160-742 · GlaxoSmithKline Biologicals SA
Key facts
| Product NDC | 58160-742 |
|---|---|
| Proprietary name | Arepanrix |
| Nonproprietary name | Influenza A H5 Monovalent Vaccine |
| Dosage form | KIT |
| Labeler | GlaxoSmithKline Biologicals SA |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA125419 |
| Marketing start | May 11, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: